AMLX — Amylyx Pharmaceuticals Balance Sheet
0.000.00%
- $474.91m
- $298.41m
- $87.37m
- 30
- 11
- 80
- 34
Annual balance sheet for Amylyx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12.9 | 96.1 | 347 | 371 | 177 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 15.3 | 40 | 0.447 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13.6 | 105 | 382 | 465 | 189 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.151 | 0.474 | 8.13 | 6.41 | 2.73 |
Other Long Term Assets | |||||
Total Assets | 14.1 | 106 | 391 | 517 | 194 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 7.33 | 17.4 | 46.6 | 82 | 28.4 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.77 | 17.4 | 50.8 | 84 | 28.9 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 5.34 | 88.2 | 341 | 433 | 165 |
Total Liabilities & Shareholders' Equity | 14.1 | 106 | 391 | 517 | 194 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |